AUPH תחזית צמיחת רווח נקי למניה לשנה הבאה Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals (AUPH) has developed a unique targeted drug that prevents dialysis in severe lupus. The company is currently scaling sales of Lupkynis and optimizing costs to position itself for a potential acquisition. Patent protection within the rare disease niche guarantees high margins. Expected EPS growth for the company next year is clearly illustrated on this chart, and 19.40 represents the latest value for this metric.
פילוחים אנליטיים ודוחות נתונים של חברת Aurinia Pharmaceuticals Inc (AUPH)

This indicator aggregates Wall Street consensus forecasts for next year's earnings growth, converting institutional investor expectations into a dynamic vector of fundamental value. For Aurinia Pharmaceuticals (AUPH), a leader in lupus nephritis therapy, the vector of forward EPS estimate changes reflects market confidence in the commercial success of its unique oral drug and the potential for revenue scaling within the immunology segment.